Key clinical point: Intraperitoneal infusions of peginterferon alfa-2b and interferon gamma-1b, administered with or without autologous monocytes, exhibited antitumor activity and tolerability in ovarian cancer.

Major finding: A partial response occurred in two patients, each with a roughly 30% reduction in target lesion size.

Study details: A phase 1 study of 18 patients (11 evaluable) with metastatic or unresectable ovarian cancer that was platinum resistant or refractory.

Disclosures: The National Institutes of Health funded the study. Dr. Cole reported having no disclosures.